- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
SHANGHAI, Sep. 22, 2016 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
In April 2015 WuXi Biologics announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city. The first phase of construction is complete and commences operation today after 17 months. The new facility accommodates two 1000L disposable bioreactors for perfusion processes and is the largest perfusion biologics manufacturing facility to date in Asia implementing disposable bioreactors.
This added capacity will support WuXi Biologics’ robust biologics commercial manufacturing pipeline and enable WuXi Biologics to maintain its position as the premier biologics manufacturer in China as well as a leader worldwide. The new commercial biologics manufacturing facility will also address the needs of Chinese companies as Marketing Authorization Holder (MAH) system is currently being piloted.
“The opening of the new commercial manufacturing facility marks another milestone for WuXi Biologics,” said Dr. Ge Li, Chairman of WuXi Biologics, “We will uphold the highest quality standards to expedite global development of biologics for both international and domestic clients.”
“This new facility further strengthens WuXi Biologics’ capabilities in integrated biologics discovery, development, and manufacturing services,” said Dr. Chris Chen, CEO of WuXi Biologics, “WuXi Biologics is committed to providing a seamless, truly ONE-stop service for our partners and clients from concept to commercialization. ”